Industry Reports

Q2 2019
A historically tight labor market where job openings consistently outpace hiring coupled with an aging US population and greater healthcare utilization continues to bolster demand as well as deal activity within the Healthcare Staffing sector.
Q2 2019
The global Medical Device Outsourcing (MDO) market reached a reported$94.2 billion in 2018, according to Grand View Research,1 and has enjoyed solid growth over the last decade as a result of the aging population and escalating prevalence of chronic diseases.
Q2 2019
The well-managed, nonopportunistic use of outsourcing to support drug development and, in particular, the development and manufacturing functions, allows sponsor-innovators to take advantage of specialist expertise, resulting in higher compliance and productivity levels, shorte
Q1 2019
The Behavioral Healthcare Services industry experienced a banner year of merger and acquisition (M&A) activity in 2018. The number of transactions increased 59% year-over-year to reach a historic industry high of 97 announced or closed transactions.
Q1 2019
Amid the growing economy and the tight labor market, the Healthcare Staffing industry has flourished.
Q1 2019
Merger and acquisition activity in the Pharmaceutical Outsourcing industry remained strong in 2018, with 63 announced or closed transactions compared to 57 in 2017. Factors driving activity include robust drug pipelines, increasing complexity of trials and drug manufacturing, and more stringent regulatory scrutiny.
Q1 2019
In our third quarterly edition of our Institutional Industry Report on the Bio/Pharma Outsourced Services (BPOS) sector, we focus on the BPOS industry’s opportunities to support the development and manufacture of cannabinoid-based drugs. We hasten, however, to dampen any prurient interest in this topic by emphasizing that these drugs have no “mind-altering” effects and will not be available through the marijuana dispensaries popping up like flowers in the spring.
Q1 2019
One of the hurdles consistently facing medical device original equipment manufacturers is the significant costs and length of time to design, develop, and secure regulatory clearance for a new product.
Q4 2018
The cell and gene therapy community gathered recently in La Jolla at the annual “Meeting on the Mesa” of the Alliance for Regenerative Medicine to review the state of the industry. The mood was ebullient as attendees celebrated the emergence of the industry from “R&D/developmental puberty” into commercial adulthood. The clear consensus was that cell/gene therapy, benefiting from substantial R&D and development efforts over the last two decades, has come of age in its ability to provide trans-formative new treatments for patients.
Q4 2018
Within the Behavioral Healthcare Services industry, companies that offered child and youth-oriented services accounted for 24.3% or 17 of the announced or closed mergers and acquisitions year-to-date. Activity in this segment has largely been driven by the national rise in children with autism (a 15.0% increase from 2016 to 2018, according to Autism Speaks) and the ongoing battle against opioid abuse (which is most prevalent among young adults ages 18-to-25 years old).

Pages